Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
809
mi
from
Suwanee, GA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
809
mi
from
Suwanee, GA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
611
mi
from
Chicago, IL
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
611
mi
from
Chicago, IL
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1124
mi
from
Chevy Chase, MD
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1124
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1147
mi
from
Towson, MD
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1147
mi
from
Towson, MD
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
862
mi
from
Chesterfield, MI
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
862
mi
from
Chesterfield, MI
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
203
mi
from
Lee's Summit, MO
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
203
mi
from
Lee's Summit, MO
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
335
mi
from
Mexico, MO
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
335
mi
from
Mexico, MO
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1288
mi
from
Brooklyn, NY
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1288
mi
from
Brooklyn, NY
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1301
mi
from
Lake Success, NY
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1301
mi
from
Lake Success, NY
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1333
mi
from
Stony Brook, NY
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1333
mi
from
Stony Brook, NY
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1043
mi
from
Chapel Hill, NC
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1043
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
957
mi
from
Charlotte, NC
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
957
mi
from
Charlotte, NC
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
815
mi
from
Columbus, OH
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
815
mi
from
Columbus, OH
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
152
mi
from
Tulsa, OK
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
152
mi
from
Tulsa, OK
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1384
mi
from
Portland, OR
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1384
mi
from
Portland, OR
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
974
mi
from
Pittsburgh, PA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
618
mi
from
Nashville, TN
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
618
mi
from
Nashville, TN
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
790
mi
from
Ogden, UT
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
790
mi
from
Ogden, UT
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
954
mi
from
Christiansburg, VA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
954
mi
from
Christiansburg, VA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1016
mi
from
Danville, VA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1016
mi
from
Danville, VA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
1186
mi
from
Norfolk, VA
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
1186
mi
from
Norfolk, VA
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
574
mi
from
Madison, WI
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
574
mi
from
Madison, WI
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
632
mi
from
Milwaukee, WI
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
632
mi
from
Milwaukee, WI
Click here to add this to my saved trials
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated:  1/25/2018
GSK Investigational Site
mi
from
Bankstown,
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease
Status: Enrolling
Updated: 1/25/2018
GSK Investigational Site
mi
from
Bankstown,
Click here to add this to my saved trials
Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.
Status: Enrolling
Updated:  1/25/2018
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD
A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.
Status: Enrolling
Updated: 1/25/2018
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
Pilot Randomized Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal and Gastric Microbiome
Status: Enrolling
Updated:  1/25/2018
Columbia University Medical Center
1286
mi
from
New York, NY
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
Pilot Randomized Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal and Gastric Microbiome
Status: Enrolling
Updated: 1/25/2018
Columbia University Medical Center
1286
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Mayo Clinic
840
mi
from
Phoenix, AZ
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Mayo Clinic
840
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
University of Florida
1049
mi
from
Gainesville, FL
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
University of Florida
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
University of Miami / Center for Liver Diseases
1320
mi
from
Miami, FL
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
University of Miami / Center for Liver Diseases
1320
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Norman Gitlin, MD
801
mi
from
Atlanta, GA
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Norman Gitlin, MD
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Digestive Helathcare of Georgia
801
mi
from
Atlanta, GA
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Digestive Helathcare of Georgia
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Henry Ford Health System
841
mi
from
Detroit, MI
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Henry Ford Health System
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Gastroenterology Associates of Western Michigan, PLC, d.b.a. West Michigan Clinical Research
728
mi
from
Wyoming, MI
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Gastroenterology Associates of Western Michigan, PLC, d.b.a. West Michigan Clinical Research
728
mi
from
Wyoming, MI
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Kansas City Gastroenterology & Hepatology
195
mi
from
Kansas City, MO
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Kansas City Gastroenterology & Hepatology
195
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
University of Nebraska Medical Center/The Nebraska Medical Center
260
mi
from
Omaha, NE
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
University of Nebraska Medical Center/The Nebraska Medical Center
260
mi
from
Omaha, NE
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
North Shore-Long Island Jewish Health System / Division of Gastroenterology
1302
mi
from
Manhasset, NY
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
North Shore-Long Island Jewish Health System / Division of Gastroenterology
1302
mi
from
Manhasset, NY
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center
1225
mi
from
New York, NY
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center
1225
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Consultants for Clinical Research Inc.
725
mi
from
Cincinnati, OH
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Consultants for Clinical Research Inc.
725
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
CHI St. Luke's Health Baylor College of Medicine Medical Center-Advanced Liver Therapies
572
mi
from
Houston, TX
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
CHI St. Luke's Health Baylor College of Medicine Medical Center-Advanced Liver Therapies
572
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Bon Secours St. Mary's Hospital of Richmond
1166
mi
from
Newport News, VA
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Bon Secours St. Mary's Hospital of Richmond
1166
mi
from
Newport News, VA
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Digestive and Liver Disease Specialists
1186
mi
from
Norfolk, VA
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Digestive and Liver Disease Specialists
1186
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
University of Calgary Liver Unit (Heritage Medical Research Clinic)
1214
mi
from
Calgary,
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
University of Calgary Liver Unit (Heritage Medical Research Clinic)
1214
mi
from
Calgary,
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
University of California, Davis Medical Center
1283
mi
from
Sacramento, CA
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
University of California, Davis Medical Center
1283
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
NYU Langone Medical Center
1288
mi
from
New York, NY
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
NYU Langone Medical Center
1288
mi
from
New York, NY
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Pinnacle Clinical Research
566
mi
from
Live Oak, TX
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Pinnacle Clinical Research
566
mi
from
Live Oak, TX
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
American Research Corporation at Texas Liver Institute
575
mi
from
San Antonio, TX
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
American Research Corporation at Texas Liver Institute
575
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
Indiana University Hospital - Clinical Research Center
642
mi
from
Indianapolis, IN
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
Indiana University Hospital - Clinical Research Center
642
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated:  1/25/2018
St. Louis University School of Medicine
415
mi
from
Saint Louis, MO
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Status: Enrolling
Updated: 1/25/2018
St. Louis University School of Medicine
415
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
Identification of Features Associated With Dysplasia Using the NvisionVLE® Imaging System Pilot Trial
Status: Enrolling
Updated:  1/25/2018
UC Irvine Medical Center
1154
mi
from
Irvine, CA
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
Identification of Features Associated With Dysplasia Using the NvisionVLE® Imaging System Pilot Trial
Status: Enrolling
Updated: 1/25/2018
UC Irvine Medical Center
1154
mi
from
Irvine, CA
Click here to add this to my saved trials
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
Identification of Features Associated With Dysplasia Using the NvisionVLE® Imaging System Pilot Trial
Status: Enrolling
Updated:  1/25/2018
The Mayo Clinic
515
mi
from
Rochester, MN
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
Identification of Features Associated With Dysplasia Using the NvisionVLE® Imaging System Pilot Trial
Status: Enrolling
Updated: 1/25/2018
The Mayo Clinic
515
mi
from
Rochester, MN
Click here to add this to my saved trials